AI Article Synopsis
- The meta-analysis aimed to compare the effectiveness of whole-brain radiotherapy (WBRT) combined with temozolomide (TMZ) against WBRT alone for treating brain metastases from non-small-cell lung cancer (NSCLC).
- Twelve randomized controlled trials with 925 participants were analyzed, revealing significant improvements in overall response rates and increased gastrointestinal and hematological adverse reactions in patients receiving WBRT plus TMZ.
- However, there was no significant change in headache incidence between the two treatment groups, supporting that WBRT combined with TMZ enhances treatment effectiveness without increasing headache frequency.
Article Abstract
The aim of this meta-analysis was to compare the efficiency of whole-brain radiotherapy (WBRT) plus temozolomide (TMZ) with WBRT for the treatment of brain metastases from non-small-cell lung cancer (NSCLC). For dichotomous variables, outcomes were reported as relative risk ratio (RR) and 95% confidence interval (CI) was used to investigate the following outcome measures: overall response rate, headache, gastrointestinal adverse reactions, and hematological adverse reactions. Twelve randomized controlled trials involving 925 participants (480 received WBRT plus TMZ; 445 received WBRT) were included in the meta-analysis. There was a significant difference between the overall response rate (RR = 1.40, 95% CI 1.24-1.57; Z = 5.51; P < 0.00001), gastrointestinal adverse reactions (RR = 1.46, 95% CI 1.05-2.04; Z = 2.27; P = 0.02), and hematological adverse reactions (RR = 1.45, 95% CI 1.04-2.02; Z = 2.21; P = 0.03) of patients treated with WBRT plus TMZ compared with patients treated with WBRT alone. There was no significant difference between headaches (RR = 1.11, 95% CI 0.93-1.02; Z = 1.13; P = 0.26) in patients treated with WBRT plus TMZ compared with patients treated with WBRT alone. In conclusion, the currently available evidence shows that WBRT plus TMZ increases the overall response rate in patients with brain metastases of NSCLC compared with WBRT alone.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911624 | PMC |
| http://dx.doi.org/10.1002/cam4.1306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of Radiotherapy in the Management of Melanoma Brain Metastases: An Overview.
Curr Treat Options Oncol
January 2025
Ella Lemelbaum Institute for Immuno Oncology, Chaim Sheba Medical Center, 6997801, Tel Aviv, Israel.
Clinical management of melanoma brain metastases is complex and requires multidisciplinary approach. With close collaboration between neurosurgeons, radiation oncologists and medical oncologists, melanoma patients with brain are offered different treatment modalities: surgery, radiation therapy, systemic therapy or combined treatments. Radiation therapy (whole brain radiotherapy- WBRT and stereotactic radiosurgery- SRS) is an integral part of treating melanoma brain metastases.
View Article and Find Full Text PDFAtypical Cerebral Carcinoids Treated with Hippocampal-Sparing Whole Brain Radiotherapy.
Cureus
December 2024
Radiation Oncology, University of Kentucky, Lexington, USA.
Central nervous system (CNS) metastases of atypical carcinoid tumors are exceptionally rare. Isolated studies suggest a survival benefit in patients who receive whole-brain radiotherapy (WBRT); however, it has been known to have detrimental effects on long-term memory and executive function. Here, we present a case of a patient initially diagnosed with stage IIB bronchopulmonary carcinoid who later developed hepatic and intracranial metastases despite receiving adjuvant systemic therapy over a two-year period.
View Article and Find Full Text PDFLeft atrial myxoma metastasizing to the brain: a case report and review of literature.
Radiat Oncol J
December 2024
London Health Sciences Centre, Schulich School of Medicine, Western University, London, ON, Canada.
Cardiac myxomas, the most common primary cardiac tumors, are believed to originate from multipotent mesenchymal cells. Approximately 75% of myxomas occur within the left atrium, increasing the risk of systemic thromboembolic events. While typically benign, atrial myxomas can rarely metastasize to the brain, with fewer than 60 cases reported.
View Article and Find Full Text PDFRole of memantine to mitigate radiation-induced cognitive dysfunction in brain metastasis patient receiving whole brain radiotherapy: a systematic review.
Radiat Oncol J
December 2024
Department of Radiotherapy, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Purpose: Identifying comprehensively the evidence of neuroprotective effects of memantine for preserving cognitive function in brain metastasis patients receiving whole brain radiotherapy (WBRT).
Methods: We searched randomized clinical trials (RCTs) analyzing the effects of memantine to preserve cognitive function in patients with brain metastasis treated with WBRT, performed in some databases, including PubMed, Embase, and Cochrane Library. The protocol was registered at PROSPERO (CRD42023476632).
Healing by secondary intention over NeoDura applicated on a craniectomy defect: a case report and literature review.
J Med Case Rep
December 2024
UZ Leuven, Plastic, Reconstructive and Aesthetic Surgery, Herestraat 49, 3000, Louvain, Belgium.
Background: NeoDura (Medprin Biotech Gmbh) is an absorbable dural repair patch consisting of degradable poly-L-lactic acid and porcine gelatin that provides a hermetic closure of the dura mater (Medprin Biotech. Neodura. Dural Repair Patch [Brochure].
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!